Drug derived from curcumin may help treat stroke

March, 2011

More evidence for the value of the curry spice curcumin comes from animal studies indicating a curcumin-derived drug may help treat stroke.

A new molecular compound derived from curcumin (found in turmeric) holds promise for treating brain damage caused by stroke. Turmeric has a long history of use in Ayurvedic and Chinese traditional medicine. However, curcumin has several important drawbacks as far as treating stroke is concerned — mainly because it can’t cross the blood-brain barrier. The new compound can.

In rabbit experiments, the drug was effective when administered up to an hour after stroke, which correlates with about three hours in humans. This is the same time frame for which tPA — the only drug currently approved for ischemic stroke — is currently approved.

The new drug is expected to move to human clinical trials soon.

Reference: 

Paul A. Lapchak presented these findings at the American Heart Association International Stroke Conference in Los Angeles on February. 9.

Related News

A study involving 254 people with dementia living at home has found that 99% of people with dementia and 97% of their caregivers had one or more unmet needs, 90% of which were safety-related.

A new U.S. study suggests that Alzheimer's disease and other dementias are markedly under-reported on death certificates and medical records. Death certificates tend to only provide an immediate cause, such as pneumonia, and don’t mention the underlying condition that provoked it.

It’s often argued that telling people that they carry genes increasing their risk of Alzheimer’s will simply upset them to no purpose. A new study challenges that idea.

11 new genetic susceptibility factors for Alzheimer’s identified

Understanding a protein's role in familial Alzheimer's disease

Analysis of data from 237 patients with mild cognitive impairment (mean age 79.9) has found that, compared to those carrying the ‘normal’ ApoE3 gene (the most common variant of the ApoE gene), the ApoE4 carriers showed markedly greater rates of shrinkage in 13 of 15 brain regions thought to be k

Analysis of data from more than 8,000 people, most of them older than 60, has revealed that, among the 5,000 people initially tested cognitively normal, carrying one copy of the “Alzheimer’s gene” (ApoE4) only slightly increased men’s risk of developing

Analysis of 700 subjects from the Alzheimer's Disease Neuroimaging Initiative has revealed a genetic mutation (rs4728029) that’s associated with people who develop Alzheimer’s pathology but don’t show clinical symptoms in their lifetime.

Analysis of brain scans and cognitive scores of 64 older adults from the NIA's Baltimore Longitudinal Study of Aging (average age 76) has found that, between the most cognitively stable and the most declining (over a 12-year period), there was no significant difference in the total amount of amy

A pilot study involving 94 older adults, of whom 18 had Alzheimer’s, 24 had

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news